Pharmaceutical Giants Brace for Billions in Sales at Risk as Major Drug Patents Expire

Big pharmaceutical companies face upcoming patent expiries on major drugs between now and 2030 that will put tens of billions in sales at risk. Companies are developing new drug formulations, pursuing acquisitions, and expanding pipelines to offset expected revenue declines from patent expiries. Biosimilars have had less market impact than generics so far, but will gradually cut into biologic revenues over time. Medicare's new drug price negotiation program adds uncertainty but may affect pre-patent expiry revenues more than post-patent competition.